alagebrium

Small moleculeexperimental

Alagebrium was a drug candidate developed by Alteon, Inc. It was the first drug candidate to be clinically tested for the purpose of breaking the crosslinks caused by advanced glycation endproducts (AGEs), thereby reversing one of the main mechanisms of aging. Through this effect Alagebrium is designed to reverse the stiffening of blood vessel walls that contributes to hypertension and cardiovascular disease, as well as many other forms of degradation associated with protein crosslinking. Alagebrium has proven effective in reducing systolic blood pressure and providing therapeutic benefit for patients with diastolic heart failure. — Wikipedia

Clinical trial activity

13 trials · 14 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
12
Phase 3
1
Phase 4
0

Earliest trial started Aug 1, 2001 (NCT00045994)

Timeline

2000s

  1. Jan 1, 2001

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

Cc1sc[n+](CC(=O)c2ccccc2)c1C
Mol. weight
232.33 g/mol
Lipinski Ro5
Pass
Rule of 3
Yes
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 3-phenacyl-4,5-dimethylthiazolium chloride
  • alagebrium
  • alagebrium
  • alagebrium
  • alagebrium
  • alagebrium
  • alagebrium chloride
  • alagebrium chloride
  • alt711
  • alt 711
  • alt-711
  • alt-711
  • alt-711
  • alt-711
  • phenyl-4,5-dimethylthiazolium chloride

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01417663Phase 2/Phase 3 (Phase 3)Nov 1, 2008Dutch Heart Foundation, Radboud University, Synvista Therapeutics, Inc
NCT00739687Phase 2Aug 1, 2008Synvista Therapeutics, Inc
NCT01014572Phase 2Jul 1, 2008The University of Texas, Dallas
NCT00662116Phase 2Mar 1, 2008Synvista Therapeutics, Inc, University of Michigan
NCT01913301Phase 2Dec 1, 2007Cardiovascular Clinical Studies, Inc.
NCT00557518Phase 2Nov 1, 2007Juvenile Diabetes Research Foundation, Monash University, Synvista Therapeutics, Inc
NCT00516646Phase 2Aug 1, 2007Synvista Therapeutics, Inc, University of Groningen
NCT00302250Phase 2Feb 1, 2006Johns Hopkins University, National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Synvista Therapeutics, Inc
NCT00089713Phase 2Mar 1, 2004Synvista Therapeutics, Inc
NCT00277875Phase 2Feb 1, 2004Johns Hopkins University, National Institutes of Health (NIH), Synvista Therapeutics, Inc
NCT00043836Phase 2Jul 1, 2002Medical University of South Carolina, Synvista Therapeutics, Inc, Wake Forest University
NCT00045981Phase 2Oct 1, 2001Synvista Therapeutics, Inc
NCT00045994Phase 2Aug 1, 2001Synvista Therapeutics, Inc
Showing 13 of 13 trials
Page 1 / 1

Organizations

Research & Development (14)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Synvista Therapeutics, IncFor profit111022001
Johns Hopkins UniversityAcademic/Hospital2012004
National Institutes of Health (NIH)Government2012004
Cardiovascular Clinical Studies, Inc.For profit1112007
Dutch Heart FoundationAcademic/Hospital1012008
Juvenile Diabetes Research FoundationAcademic/Hospital1012007
Medical University of South CarolinaAcademic/Hospital1012002
Monash UniversityAcademic/Hospital1012007
National Heart, Lung, and Blood Institute (NHLBI)Government1012006
Radboud UniversityAcademic/Hospital1112008
The University of Texas, DallasAcademic/Hospital1112008
University of GroningenAcademic/Hospital1012007
University of MichiganAcademic/Hospital1012008
Wake Forest UniversityAcademic/Hospital1012002
14 organizations
Page 1 / 1